systhiperСистемные гипертензииSystemic Hypertension2075-082X2542-2189LLC «ИнтерМедсервис»10.26442/2075082X.2020.2.200237systhiper-630Research ArticleОБЗОРREVIEWНовые возможности снижения сердечно-сосудистого риска в Российской ФедерацииNew opportunities for reducing cardiovascular risk in the Russian FederationОстроумоваО. Д.OstroumovaO. D.info@eco-vector.comСергиенкоИ. В.SergienkoI. V.info@eco-vector.comЖернаковаЮ. В.ZhernakovaYu. V.info@eco-vector.comФГБУ «НМИЦ кардиологии» Минздрава РоссииРоссияFSBI "National Medical Research Center of Cardiology" of the Ministry of Health of RussiaRussian FederationФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава РоссииРоссияNational Medical Research Center for CardiologyRussian FederationИнститут клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии» Минздрава РоссииРоссияInstitute of Clinical Cardiology. A.L. Myasnikov Federal State Budgetary Institution "National Medical Research Center of Cardiology" of the Ministry of Health of RussiaRussian Federation2020231220221729197Copyright © Остроумова О.Д., Сергиенко И.В., Жернакова Ю.В., 20222022Остроумова О.Д., Сергиенко И.В., Жернакова Ю.В.Ostroumova O.D., Sergienko I.V., Zhernakova Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.syst-hypertension.ru/jour/article/view/630

VIII Евразийский конгресс кардиологов. Обзор симпозиумов. Новые возможности снижения сердечно-сосудистого риска в Российской Федерации. Системные гипертензии.

VIII Eurasian Congress of Cardiology. Overview of symposiums. New opportunities for reducing cardiovascular risk in the Russian Federation. Systemic Hypertension

ReferencesKannel WB et al. 1971Kannel WB et al. 1971Rutan GH et al. 1988Rutan GH et al. 1988Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355 (9207): 865-72. DOI: 10.1016/s0140-6736(99)07330-4Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355 (9207): 865-72. DOI: 10.1016/s0140-6736(99)07330-4Neaton JD et al. JAMA 1993Neaton JD et al. JAMA 1993Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. DOI: 10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104. DOI: 10.1093/eurheartj/ehy339Российские рекомендации по лечению артериальной гипертензии. 2019Российские рекомендации по лечению артериальной гипертензии. 2019Chudek J. Ocena profilu bezpieczeństwa stosowania produktu EgiramlonRwpopulacji polskich pacjentów (EG/NT/2012/018) - edycje 1-5 ŚWIAT MEDYCYNY I FARMACJI 84 KWIECIEŃ 2015Chudek J. Ocena profilu bezpieczeństwa stosowania produktu EgiramlonRwpopulacji polskich pacjentów (EG/NT/2012/018) - edycje 1-5 ŚWIAT MEDYCYNY I FARMACJI 84 KWIECIEŃ 2015ASCOT study (Anglo-Scandinavian Cardiac Outcomes Trial). 2005ASCOT study (Anglo-Scandinavian Cardiac Outcomes Trial). 2005Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97VALUE studyVALUE studyPitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurence of clinical events. PREVENT Investigatiors. Circulation 2000; 102: 1503-10Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurence of clinical events. PREVENT Investigatiors. Circulation 2000; 102: 1503-10The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 2000; 342:145-53The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 2000; 342:145-53AIREX studyAIREX studyMICROHOPE studyMICROHOPE studySECURE studySECURE studyASCOT-BPLA studyASCOT-BPLA studyOpie et al. Drug Heart 1991Opie et al. Drug Heart 1991White WB, Viadero JJ, Lane TJ et al. Effects of combination therapy with captopnil and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 1986; 39: 43-8White WB, Viadero JJ, Lane TJ et al. Effects of combination therapy with captopnil and nifedipine in severe or resistant hypertension. Clin Pharmacol Ther 1986; 39: 43-8Gustrafsson J Cardiovasc Phar 1987; 10 (Suppl. 1): 21-31Gustrafsson J Cardiovasc Phar 1987; 10 (Suppl. 1): 21-31Кътова Ц., Симова Я., Костова В. Антихпертензивна ефективност Egiramlon - ефекти във времето. Кардио D Брой. 2015; 3: 4-6Кътова Ц., Симова Я., Костова В. Антихпертензивна ефективност Egiramlon - ефекти във времето. Кардио D Брой. 2015; 3: 4-6Tomsсany J et al. RAMONA study Hypertonia es Nephrologia 2013; 17 (2): 49-96Tomsсany J et al. RAMONA study Hypertonia es Nephrologia 2013; 17 (2): 49-96Tomsсany J et al. RAMSES study Hypertonia es Nephrologia 2013; 19 (5-6): 15-21Tomsсany J et al. RAMSES study Hypertonia es Nephrologia 2013; 19 (5-6): 15-21Olszanecka-Glinianowicz M, Smertka M, Almgren-Rachtan A et al. Ramipril/amlodipine single pill - Effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status. Pharmacol Rep 2014; 66: 1043-9Olszanecka-Glinianowicz M, Smertka M, Almgren-Rachtan A et al. Ramipril/amlodipine single pill - Effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status. Pharmacol Rep 2014; 66: 1043-9Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П. и др. Изучение приверженности терапии у пациентов с метаболическим синдромом на примере нового комбинированного антигипертензивного препарата рамиприла и амлодипина по результатам наблюдательного исследования ГРАНАТ-1. Кардиоваскулярная терапия и профилактика. 2017: 16 (1)Марцевич С.Ю., Лукина Ю.В., Кутишенко Н.П. и др. Изучение приверженности терапии у пациентов с метаболическим синдромом на примере нового комбинированного антигипертензивного препарата рамиприла и амлодипина по результатам наблюдательного исследования ГРАНАТ-1. Кардиоваскулярная терапия и профилактика. 2017: 16 (1)Марцевич С. Ю., Лукина Ю. В., Кутишенко Н. П. и др. Изучение параметров переносимости и приверженности к терапии у пациентов с хронической обструктивной болезнью легких и артериальной гипертонией на фоне лечения фиксированной комбинацией рамиприла и амлодипина (по результатам наблюдательного исследования «Гранат-2»). Рациональная фармакотерапия в кардиология. 2017: 13 (2)Марцевич С. Ю., Лукина Ю. В., Кутишенко Н. П. и др. Изучение параметров переносимости и приверженности к терапии у пациентов с хронической обструктивной болезнью легких и артериальной гипертонией на фоне лечения фиксированной комбинацией рамиприла и амлодипина (по результатам наблюдательного исследования «Гранат-2»). Рациональная фармакотерапия в кардиология. 2017: 13 (2)ONTARGET studyONTARGET studyThe Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. N Engl J Med 2000; 342: 154-60The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E Supplementation and Cardiovascular Events in High-Risk Patients. N Engl J Med 2000; 342: 154-60Verdecchia P, Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104 (17): 2039-44Verdecchia P, Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104 (17): 2039-44Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 1002; 359 (9311): 995-1003Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 1002; 359 (9311): 995-1003Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41-6Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41-6Dzau VJ, Bernstein K, Celermajer D et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (9A): 1L-20LDzau VJ, Bernstein K, Celermajer D et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88 (9A): 1L-20LAgabiti-Rosei E, Ambrosioni E, dal Palu C et al., on behalf of the RACE Study Group: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular hypertrophy in hypertension: results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertens 1995; 13: 1325-34Agabiti-Rosei E, Ambrosioni E, dal Palu C et al., on behalf of the RACE Study Group: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular hypertrophy in hypertension: results of the RACE (Ramipril Cardioprotective Evaluation) study. J Hypertens 1995; 13: 1325-34Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-63Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857-63Willoughby SR, Rajendran S, Chan WP. Ramipril Sensitizes Platelets to Nitric Oxide. J Am College Cardiol 2012; 60 (10): 887-94Willoughby SR, Rajendran S, Chan WP. Ramipril Sensitizes Platelets to Nitric Oxide. J Am College Cardiol 2012; 60 (10): 887-94Simonyi G, Ferenci T, Finta E. Fixed combinations of renin-angiotensin-aldosterone system inhibitors and calcium channel blockers in relation of patients adherence in hypertension. Eur Heart J 2018; 39 (Suppl.): 398Simonyi G, Ferenci T, Finta E. Fixed combinations of renin-angiotensin-aldosterone system inhibitors and calcium channel blockers in relation of patients adherence in hypertension. Eur Heart J 2018; 39 (Suppl.): 398Franse LV, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18 (8): 1149-54Franse LV, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18 (8): 1149-54Lehto S, Niskanen L, Ronnemaa T et al. Serum Uric Acid Is a Strong Predictor of Stroke in Patients With Non Insulin-Dependent Diabetes Mellitus. Stroke 1998; 29 (3): 635-9Lehto S, Niskanen L, Ronnemaa T et al. Serum Uric Acid Is a Strong Predictor of Stroke in Patients With Non Insulin-Dependent Diabetes Mellitus. Stroke 1998; 29 (3): 635-9Ежов М.В., Сергиенко И.В., Кухарчук В.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. 2020Ежов М.В., Сергиенко И.В., Кухарчук В.В. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. 2020Neumann FJ, Sousa-Uv M, Ahlsson A et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40 (2): 87-165Neumann FJ, Sousa-Uv M, Ahlsson A et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40 (2): 87-165Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. ESC Congress, Munich 2018. Eur J Prev Cardiol 2019; 26 (8): 824-35Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. ESC Congress, Munich 2018. Eur J Prev Cardiol 2019; 26 (8): 824-35Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92 (2): 152-60Jones PH, Davidson MH, Stein EA et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92 (2): 152-60Wolffenbuttel BH, Franken AA, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005; 257 (6): 531-9Wolffenbuttel BH, Franken AA, Vincent HH. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL study. J Intern Med 2005; 257 (6): 531-9Clearfield M, Kallend D, Palmerz M. W16-P-014 Efficacy and safety of rosuvastatin 10 MG versus atorvastatin 20 MG: Results of the pulsar study. Atherosclerosis Supplements. 2005; 6(1): 104Clearfield M, Kallend D, Palmerz M. W16-P-014 Efficacy and safety of rosuvastatin 10 MG versus atorvastatin 20 MG: Results of the pulsar study. Atherosclerosis Supplements. 2005; 6(1): 104Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705-12Pitt B, Loscalzo J, Yčas J et al. Lipid levels after acute coronary syndromes. J Am College Cardiol 2008; 51 (15): 1440-5Pitt B, Loscalzo J, Yčas J et al. Lipid levels after acute coronary syndromes. J Am College Cardiol 2008; 51 (15): 1440-5Nicholls SJ, Brandrup-Wognsen G, Palmer M et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010; 105 (1): 69-76Nicholls SJ, Brandrup-Wognsen G, Palmer M et al. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010; 105 (1): 69-76William S, Weintraub WS. Perspective on Trends in Statin Use. JAMA Cardiology 2017; (1): 11-2William S, Weintraub WS. Perspective on Trends in Statin Use. JAMA Cardiology 2017; (1): 11-2Redelmeier DA, Manzoor F, Thiruchelvam D. Association Between Statin Use and Risk of Dementia After a Concussion. JAMA Neurology 2019; 76 (8): 887-96Redelmeier DA, Manzoor F, Thiruchelvam D. Association Between Statin Use and Risk of Dementia After a Concussion. JAMA Neurology 2019; 76 (8): 887-96Wingo TS, Cutle DJ, Wingo AP et al. Association of Early-Onset Alzheimer Disease With Elevated Low-density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB. JAMA Neurology 2019; 76 (7): 809-17Wingo TS, Cutle DJ, Wingo AP et al. Association of Early-Onset Alzheimer Disease With Elevated Low-density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB. JAMA Neurology 2019; 76 (7): 809-17Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Eng J Med 2015; 372 (25): 2387-97Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Eng J Med 2015; 372 (25): 2387-97Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014; 10 (2): 153-9Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014; 10 (2): 153-9Zhu Y, Pandya BJ, Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63 (10): 3136-41Zhu Y, Pandya BJ, Choi H.K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63 (10): 3136-41Bickel C, Rupprecht HJ, Blankenberg S et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89 (1): 12-7Bickel C, Rupprecht HJ, Blankenberg S et al. Serum uric acid as an independent predictor of mortality in patients with angiographically proven coronary artery disease. Am J Cardiol 2002; 89 (1): 12-7Wong KYK, Macwalter RS, Fraser HW et al. Struthers, Urate predicts subsequent cardiac death in stroke survivors, Eur Heart J 2002; 23 (10): 788-93Wong KYK, Macwalter RS, Fraser HW et al. Struthers, Urate predicts subsequent cardiac death in stroke survivors, Eur Heart J 2002; 23 (10): 788-93Borghi C, Tykarski A, Widecka K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J 2018; 25 (5): 545-64Borghi C, Tykarski A, Widecka K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J 2018; 25 (5): 545-64Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16 (4): 8-21. DOI: 10.26442/2075082X.2019.4.190686Чазова И.Е., Жернакова Ю.В., Кисляк О.А. и др. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском. Системные гипертензии. 2019; 16 (4): 8-21. DOI: 10.26442/2075082X.2019.4.190686Hui M, Carr A, Cameron S et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford) 2017; 56 (7): e1-e20Hui M, Carr A, Cameron S et al. The British Society for Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford) 2017; 56 (7): e1-e20Butler R, Morri AD, Belch JJF et al. Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension. Hypertension 2002; 35 (3): 746-51Butler R, Morri AD, Belch JJF et al. Allopurinol Normalizes Endothelial Dysfunction in Type 2 Diabetics With Mild Hypertension. Hypertension 2002; 35 (3): 746-51Farquharson CAJ, Butler R, Hill A et al. Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure. Circulation 2002; 106 (2): 221-6Farquharson CAJ, Butler R, Hill A et al. Allopurinol Improves Endothelial Dysfunction in Chronic Heart Failure. Circulation 2002; 106 (2): 221-6Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300 (8): 924-32Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008; 300 (8): 924-32MacIsaac RL, Salatzki J, Higgins P et al. Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. Hypertension 2016; 67 (3): 535-40MacIsaac RL, Salatzki J, Higgins P et al. Allopurinol and Cardiovascular Outcomes in Adults With Hypertension. Hypertension 2016; 67 (3): 535-40Bredemeier M, Lopes LM, Eisenreich MA et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2018; 18: 24Bredemeier M, Lopes LM, Eisenreich MA et al. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2018; 18: 24White WB, Sa KG, Becker MA et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Eng J Med 2018; 378 (13): 1200-10White WB, Sa KG, Becker MA et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Eng J Med 2018; 378 (13): 1200-10

The authors declare that there are no conflicts of interest present.